Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Zhi‑Peng Wu
Efficacy and Safety of Baricitinib for Active Rheumatoid Arthritis in Patients With an Inadequate Response to Conventional Synthetic or Biological Disease‑modifying Anti‑rheumatic Drugs: A Meta‑analysis of Randomized Controlled Trials
Experimental and Therapeutic Medicine
Medicine
Cancer Research
Immunology
Microbiology
Related publications
Safety, Cost and Effectiveness Issues With Disease Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis
Annals of the Rheumatic Diseases
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
Efficacy and Safety of Sirukumab in Japanese Patients With Moderate to Severe Rheumatoid Arthritis Inadequately Controlled by Disease Modifying Anti-Rheumatic Drugs: Subgroup Analysis of a Phase 3 Study
Modern Rheumatology
Medicine
Rheumatology
Pms3 - Infliximab for Disease-Modifying Anti-Rheumatic Drug-Naive Rheumatoid Arthritis Patients: Systematic Review and Descriptive Analysis of Publications of Randomized Controlled Trials
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Can Disease-Modifying Anti-Rheumatic Drugs Reduce the Risk of Developing Dementia in Patients With Rheumatoid Arthritis?
Neurotherapeutics
Neurology
Pharmacology
Safety of Abatacept Compared With Other Biologic and Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: Data From an Observational Study
Arthritis Research & Therapy
OP0281-HPR Preferences of Patients With Rheumatoid Arthritis Regarding Disease Modifying Anti-Rheumatic Drugs: A Discrete Choice Experiment
AB0490 Evaluation of Inhibitory Factor of Radiographic Progression by Iguratimod Add-On Therapy in Rheumatoid Arthritis Patients With Inadequate Responses to Disease-Modifying Anti-Rheumatic Drugs
Biological Targets in the Treatment of Rheumatoid Arthritis: A Comprehensive Review of Current and In-Development Biological Disease Modifying Anti-Rheumatic Drugs
Biologics: Targets and Therapy
Oncology
Immunology
Gastroenterology
Pharmacology
Rheumatology
Allergy
Ixekizumab Is Efficacious When Used Alone or When Added to Conventional Synthetic Disease-Modifying Antirheumatic Drugs (cDMARDs) in Patients With Active Psoriatic Arthritis and Previous Inadequate Response or Intolerance to Tumour Necrosis Factor Inhibitors
RMD Open
Rheumatology
Allergy
Immunology
